A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge

Mucosal Immunology

Volumn 2, Issue 2, 2009, Pages 129-143

  Zhang, X ^a   Chentoufi, A A ^a   Dasgupta, G ^a   Nesburn, A B ^a   Wu, M ^a   Zhu, X ^a   Carpenter, D ^a   Wechsler, S L ^a,b   You, S ^c   BenMohamed, L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8+ T LYMPHOCYTE PEPTIDE EPITOPE VACCINE; LIPOPEPTIDE; PALMITIC ACID; PEPTIDE VACCINE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; EPITHELIUM CELL; FEMALE; GENITAL HERPES; GENITAL SYSTEM; HERPES SIMPLEX VIRUS 2; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; LYMPHATIC DRAINAGE; MEMORY T LYMPHOCYTE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; VAGINA MUCOSA; VIRUS LOAD; WILD TYPE;

EID: 60549095850     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2008.81     Document Type: Article

References (98)

1. Yoneyama, H. et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J. Exp. Med. 202, 425-435 (2005).
2. Tigges, M.A. et al. Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J. Virol. 66, 1622-1634 (1992).
3. Koelle, D.M. et al. Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes. J. Clin. Invest. 91, 961-968 (1993).
4. BenMohamed, L., Wechsler, S.L. & Nesburn, A.B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet. Infect. Dis. 2 425-431 (2002).
5. Koelle, D.M. Vaccines for herpes simplex virus infections. Curr. Opin. Investig. Drugs 7, 136-141 (2006).
6. Russell, M.W. Immunization for protection of the reproductive tract: A review. Am. J. Reprod. Immunol. 47, 265-268 (2002).
7. Langenberg, A.G., Corey, L., Ashley, R.L., Leong, W.P. & Straus, S.E. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N. Engl. J. Med. 341 1432-1438 (1999).
8. Celum, C., Levine, R., Weaver, M. & Wald, A. Genital herpes and human immunodeficiency virus: Double trouble. Bull. World Heafth Organ. 82, 447-453 (2004).
9. Kaul, R. et al. The genital tract immune milieu: An important determinant of HIV susceptibility and secondary transmission. J. Reprod. Immunol. 77, 32-40 (2008).
10. MasCasullo, V., Fam, E., Keller, M.J. & Herold, B.C. Role of mucosal immunity in preventing genital herpes infection. Viral. Immunol. 18, 595-606 (2005).
11. Milligan, G.N., Dudley-McClain, K.L., Chu, C.F. & Young, C.G. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Virology 318, 507-515 (2004).
12. Kwant, A. & Rosenthal, K.L. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22, 3098-3104 (2004).
13. Hamajima, K. et al. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clin. Immunol. 102, 12-18 (2002).
14. Gallichan, W.S. & Rosenthal, K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect Dis. 177 1155-1161 (1998).
15. Schleiss, M.R., Bourne, N., Jensen, N.J., Bravo, F. & Bernstein, D.I. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83. Viral. Immunol. 13, 155-167 (2000).
16. Gherardi, M.M., Perez-Jimenez, E., Najera, J.L. & Esteban, M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: Enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol. 172, 6209-6220 (2004).
17. Tengvall, S., Lundqvist, A., Eisenberg, R.J,, Cohen, G.H. & Harandi, A.M. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80, 5283-5291 (2006).
18. Rosenthal, K.L. & Gallichan, W.S. Challenges for vaccination against sexually-transmitted diseases: Induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin. Immunol. 9, 303-314 (1997).
19. Toka, E.N,, Pack, C.D. & Rouse, B.T. Molecular adjuvants for mucosal immunity. Immunol. Rev. 199, 100-112 (2004).
20. Stanberry, L.R. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 (Suppl 3),161A-169A (2004).
21. Mestecky, J., Moldoveanu, Z. & Russell, M.W. Immunologic uniqueness of the genital tract: Challenge for vaccine development. Am. J. Reprod. Immunol. 53, 208-214 (2005).
22. Moldoveanu, Z., Huang, W.O., Kulhavy, R., Pate, M.S. & Mestecky, J. Human male genital tract secretions: Both mucosal and systemic immune compartments contribute to the humoral immunity. J. Immunol. 175, 4127-4136 (2005).
23. Gill, N., Davies, E.J. & Ashkar, A.A. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am. J. Reprod. Immunol. 59, 35-43 (2008).
24. Herbst-Kralovetz, M.M. et al. Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am. J. Reprod. Immunol. 59, 212-224 (2008).
25. Soboll, G., Schaefer, T.M. & Wira, O. R. Effect of toll-like receptor (TLR) agonists on TLR and microbicide expression in uterine and vaginal tissues of the mouse. Am. J. Reprod. Immunol. 55, 434-446 (2006).
26. Zariffard, M.R. et al. Induction of tumor necrosis factor- alpha secretion and toll-like receptor 2 and 4 mRNA expression by genital mucosal fluids from women with bacterial vaginosis. J. Infect. M. 191, 1913-1921 (2005).
27. Lund, J.M., Linehan, M.M., Iijima, N. & Iwasaki, A. Cutting edge: plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J. Immunol. 177, 7510-7514 (2006).
28. Fichorova, R.N., Cronin, A.O., Lien, E., Anderson, D.J. & Ingalls, R.R. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. J. Immunol. 168, 2424-2432 (2002).
29. BenMohamed, L., Krishnan, R., Auge, C., Primus, J.F. & Diamond, D.J. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106, 113-121 (2002).
30. BenMohamed, L. et al. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32, 2274-2281 (2002).
31. Borsutzky, S. et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24, 2049-2056 (2006).
32. Batz1off, M.R., Hartas, J., Zeng, W., Jackson, D.C. & Good, M.F. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group a streptococcus challenge and reduces throat colonization. J. Infect. Dis. 194 325-330 (2006).
33. Zhu, X., Ramos, T.V., Gras-Masse, H., Kaplan, B.E. & BenMohamed, L. Lipopeptide epitopes extended by Ne-Palmitoyl lysine moiety increases uptake and maturation of dendritic cell through a toll-like receptor 2 pathway and triggers a Th1-dependent protective immunity, Eur. J. Immunol. 34, 1142-1149 (2004).
34. Zhang, X. et al. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 79, 15289-15301 (2005).
35. Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat. Immunol. 2 675-660 (2001).
36. Tengvall, S. & Harandi, A.M. Importance of myeloiel differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice. J. Reprod. Immunol. 78, 49-57 (2008).
37. BenMohamed, L. et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: Dependence on HLA class II restricted T-(H) response. Hum. Immunol. 61, 764-779 (2000).
38. Belyakov, I. M. et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge Proc. Natl. Acad. Sci. USA 95, 1709-1714 (1998).
39. Gallichan, W. S. et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166, 3451-3457 (2001).
40. Kozlowski, P. A. et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: Influence of the menstrual cycle. J. Immunol. 169 566-574 (2002).
41. Nesburn, A. B. et al. Functional Foxp3+ CD4+CD25(Bright+) "natural" regulatory T Cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection. J. Virol. 81, 6911-6919 (2007).
42. Kuklin, N. A., Daheshia, M., Chun, S. & Rouse, B. T. Role of mucosal immunity in herpes simplex virus infection. J. Immunol. 160, 5998-6003 (1998).
43. Sedlik, C. et al. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. J. Virol. 73, 2739-2744 (1999).
44. Tengvall, S., Josefsson, A., Holmgren, J. & Harandi, A. M. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. J. Reprod. Immunol. 68, 53-69 (2005).
45. Eriksson, E. M. & Jackson, D. C. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr. Protein Pept. Sci. 8, 412-417 (2007).
46. Nesburn, A. B. et al. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4, 178-187 (2006).
47. Durier, C. et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 20 1039-1049 (2006).
48. Moyle, P. M. & Toth, I. Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem. 15, 506-516 (2008).
49. Borsutzky, S. et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J. Immunol. 174, 6308-6313 (2005).
50. BenMohamed, L. et al. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77, 9463-9473 (2003).
51. Carr, D. J. Increased levels of IFN-gamma in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol. J. Neuroimmunol. 89, 160-167 (1998).
52. Nesburn, A. B. et al. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23, 873-883 (2005).
53. Kohl, S. et al. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J. Infect. Dis. 181, 335-339 (2000).
54. Gahery-Segard, H. et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: Characterization of CD8+-T-cell epitopes recognized. J. Virol. 77, 11220-11231 (2003).
55. Daubersies, P. et al. Protection against plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liverstage antigen 3. Nat. Med. 6, 1258-1263 (2000).
56. Milligan, G.N., Bernstein, D.I. & Bourne, N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160, 6093-6100 (1998).
57. Langenberg, A.G. et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity [corrected]. Ann. Intern. Med. 122, 889-898 (1995).
58. Sajic, D et al. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J. Med. Virol. 71, 561-568 (2003).
59. Pyles, R.B. et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J. Virol. 76, 11387-11396 (2002).
60. Dumais, N., Patrick, A., Moss, R.B., Davis, H.L. & Rosenthal, K.L. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 186 1098-1105 (2002).
61. Daftarian, P. et al. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 23, 3453-3468 (2005).
62. Davila, E., Kennedy, R. & Celis, E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63, 3281-3288 (2003).
63. BenMohamed, L., Thomas, A. & Druilhe, P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect. Immun. 72, 4376-4384 (2004).
64. BenMohamed, L. et al. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18, 2843-2855 (2000).
65. BenMohamed, L. et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27, 1242-1253 (1997).
66. Gahery, H. et al. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+/CD8+ T cells in humans after lipopeptide vaccination. AIDS Res. Hum. Retroviruses 23, 427-437 (2007).
67. Gahery, H. et al. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22, 684-694 (2006).
68. Chentoufi, A.A. et al. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82, 11792-11802 (2008).
69. Cottalorda, A. et al. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur. J. Immunol. 36, 1684-1693 (2006).
70. Zhao, X. et al. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J. Exp. Med. 197, 153-162 (2003).
71. Bettahi, I. et al. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest. Ophthalmol. Vis. Sci. 48, 4643-4653 (2007).
72. Bettahi, I., Zhang, X., Afifi, R.E. & BenMohamed, L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 19, 220-236 (2006).
73. Chentoufi, A.A. et al. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180, 426-437 (2008).
74. Tsunobuchi, H. et al. Memory-type CD8+ T cells protect IL-2 receptor alpha-deficient mice from systemic infection with herpes simplex virus type 2. J. Immunol. 165, 4552-4560 (2000).
75. Gyotoku, T., Ono, F. & Aurelian, L. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine 20, 2796-2807 (2002).
76. Kim, M. et al. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J. Immunol. 181, 6604-6615 (2008).
77. Morrison, L.A. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 376, 205-210(2008).
78. Koelle, D.M., Frank, J.M., Johnson, M.L. & Kwok, W.W. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpeslesions. J. Virol. 72, 7476-7483 (1998).
79. Koelle, D.M. et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest. 101, 1500-1508 (1998).
80. Bassett, I. et al. Herpes simplex virus type 2 infection of heterosexual men attending a sexual health centre. Med. J. Aust. 160, 697-700 (1994).
81. Spruance, S.L. et al. The natural history of recurren herpes simplex labialis: Implications for antiviral therapy. N. Engl. J. Med. 297, 69-75 (1977).
82. Mikloska, Z. & Cunningham, A.L. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J. Gen. Virol. 79 (Part 2), 353-361 (1998).
83. Koelle, D.M., Benedetti, J., Langenberg, A. & Corey, L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann. Intern. Med. 116, 433-437 (1992).
84. Zarling, J.M., Moran, P.A., Brewer, L., Ashley, R. & Corey, L. Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine. J. Virol. 62, 4481-4485 (1988).
85. Zarling, J.M. et al. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J. Immunol. 136 4669-4673 (1986).
86. Koelle, D.M. et al. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 68, 2803-2810 (1994).
87. Koelle, D.M., Gonzalez, J.C. & Johnson, A.S. Homing in on the cellular immune response to HSV-2 in humans. Am. J. Reprod. Immunol. 53 172-181 (2005).
88. B Koelle, D.M., Schomogyi, M. & Corey, L. Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J. Infect. Dis. 182, 662-670 (2000).
89. Koelle, D.M., Schomogyi, M., McClurkan, C., Reymond, S.N. & Chen, H.B. CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: Comparison with responses to tegument and envelope glycoproteins. J. Virol. 74, 11422-11425 (2000).
90. Khanna, K.M., Lepisto, A.J. & Hendricks, R.L. Immunity to latent viral infection: Many skirmishes but few fatalities. Trends Immunol. 25, 230-234(2004).
91. van Lint, A. et al. Herpes simplex virus-specific CD8+ T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation. J. Immunol. 172, 392-397 (2004).
92. Simmons, A. & Tscharke, D.C. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: Implications for the fate of virally infected neurons. J. Exp. Med. 175, 1337-1344 (1992).
93. Milligan, G.N., Dudley-McClain, K.L., Young, C.G. & Chu, C.F. T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice. J. Reprod. Immunol. 61, 115-127 (2004).
94. Harandi, A.M., Eriksson, K. & Holmgren, J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77, 953-962 (2003).
95. Ghiasi, H., Cai, S., Perng, G.C., Nesburn, A.B. & Wechsler, S.L. Both CD4+ and CD8+ T cells are invotved in protection against HSV-1 induced corneal scarring. Br. J. Ophthalmol. 84, 408-412 (2000).
96. Parr, M.B. et al. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest 70, 369-380 (1994).
97. Gillgrass, A.E., Ashkar, A.A., Rosenthal, K.L. & Kaushic, C. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 77, 9845-9851 (2003).
98. Suvas, S., Kumaraguru, U., Pack, C.D., Lee, S. & Rouse, B.T. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J. Exp. Med. 198, 889-901 (2003).